Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Deals workspace

Medicine and biotech M&A — therapeutics, diagnostics, medtech, and clinical women's health. Descriptive analytics from public sources only.

Medicine & biotech scope — 101 companies · 53 verified deals in this workspace. Not live market data; descriptive analytics only.

Therapeutics, diagnostics, medtech, and clinical women's health — consumer brands live in a separate workspace. View Consumer health →

What Our Data Covers

Here's an honest look at our dataset — how many deals we've verified, what's disclosed, and where our analysis is strongest.

Updated 2026-10-19

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Companies

Deals

Disclosed price

Undisclosed price

Estimand: disclosed-only observed sum (completed women's health)

· basis not recorded disclosed among completed WH deals · · basis not recorded adjacency excluded · coverage vs AOA Dx Follow the Exits (2000–2024) (n=). Not a market topline — see methods and docs/LIMITATIONS.md.

Valuation coverage

/101 companies ()

Price disclosure rate

(53 with notes)

Deal years

2012–2026

Sectors with deals

Effective n by module

Network analysis

139 nodes, 53 edges

Power: high

Competitive analysis

53 deals, 29 buyers

Power: high

Price analytics

47 disclosed prices

Power: high

Deal velocity

53 deals

Power: high

Deals by sector (target)

SectorCos.Deals$ discl.
Breast Health777
Contraception311
Dermatology111
Diagnostics181313
Fertility1295
Gynecological Surgery555
Maternal Health511
Menopause432
Pelvic Health432
Precision Medicine666
Reproductive Health744

7 sectors with companies but no verified deals omitted.

Deals by announcement year

YearDeals$ discl.
201222
201644
201722
201877
201922
202077
202166
202275
202333
2024108
202510
202621

Global source categories

  • SEC EDGAR filings (acquisitions, 8-K/10-K)
  • Crunchbase (funding rounds, where cited)
  • Company press releases and investor relations pages
  • Verified press coverage (TechCrunch, Fierce Healthcare, Business Wire, etc.)
  • Company websites (descriptions, founding dates)

+31 more in dataset provenance.

Data compiled from public sources for educational visualization. Verify independently before any commercial use.

Measurement layer

Quality grades, gated-metric publication, vintage gaps, and display provenance — read from computed artifacts, not a hardcoded pipeline panel.

Published (4/4 fully provenanced)
Withheld of 209 (98.1%)
Missing dedicated as-of (68/137)
Uncovered display sites of 911

Company source quality

avg

A 3B 39C 44D 58F 8

Deal source quality

avg

A 28B 5C 23D 1F 4

44/98 active economic records. 31 are current-only because publicAsOfDate is missing (totalFunding 22/40, lastKnownValuation 9/58). Missing dates stay missing.

/47 computedPremium rows exactly reproducible · Deal values use announcement date only (52/52) — not a value vintage. · Pre-deal valuations with date: 49/49.

Artifact v11 · hash 5a0a432d5db8 · 2026-10-19T00:00:00.000Z · 66 companies and 5 deals graded D/F

Featured deal — empowerment context

HLTH/Outcomes4Me 2022 cited survey items mapped to the featured deal by analyst curation — not live outcomes or keyword affinity.

Empowerment context — Biotheranostics

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
  • No survivorship care plan after active treatment (Clinical trial / publication)54%cited HLTH 2022Mapping source →
  • Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →

Other curated mappings on these gaps: Endomagnetics, Genomic Health, Foundation Medicine, Flatiron Health

Full cited gap matrix →

Review console

Staging candidates (SEC + manual import) live in Postgres until promoted into the verified dataset. Use this console to review, attest, preview, and promote.

Dataset 2026-10-19 · v11Build …SEC ingest — configure Postgres to enable

Queue metrics unavailable — configure Postgres to see approve/reject counts.

SEC candidate review queue

Staging rows from lacuna_deals — open a dossier to review evidence, attest promotion fields, and merge into verified JSON.

Guide: Reviewer promotion steps (E2)

Loading queue…

Checking review session…

Who's Connected to Whom

Explore the relationships between acquirers and the women's health companies they've welcomed into their portfolios.

Loading network graph

Deal Flow

Announced women's health M&A deals by year from verified public sources.

Loading dashboard section
Loading dashboard section
Advanced deal analysiscomparables, network diagnostics, acquirer patterns, outcomes, and historical context

Comparable context & historical acquisition-pattern similarity

Deterministic context engine. Heuristic comparable context and a unitless historical acquisition-pattern similarity. Not a calibrated probability and not a five-year forecast. Outcome-only stage labels are withheld.

Loading dashboard section

A Closer Look at the Network

How concentrated is the acquirer landscape? Honest statistical measures with transparent confidence intervals.

Loading dashboard section

Getting to Know the Acquirers

Who's been most active, what are they building, and how do their strategies compare?

Loading dashboard section

Did the Deal Deliver?

Checking in on what happened after the acquisition — did the outcomes match the promise?

Loading dashboard section

Finding Companies Like Each Other

Which women's health companies share similar profiles? Explore natural groupings and see how they compare.

Loading dashboard section

Exit Similarity Explorer

Deterministic context engine. Ordinal bands from fixed, disclosed factor weights. Not a fitted model and not a time-to-exit forecast. Acquired companies are a historical baseline; membership in the acquisitions array does not raise data coverage and assumption completeness.

Loading dashboard section

White Space Analysis

Sectors with high company density but low M&A activity — where the next wave may form.

Loading dashboard section

Time from founding to announcement

Descriptive Kaplan-Meier curves for companies in the top sectors with a founding year after 1990. A company-year panel is not constructible from this catalog. Companies without a founding year stay excluded, stored founding years are not an eight-year window, and missing years are not inferred. No hypothesis test is published.

Loading dashboard section